Dihydroalprenolol

Dihydroalprenolol (DHA) is a synthetic beta blocker used in scientific research. It is radiolabeled and used as a radioligand for the beta adrenergic receptor.

History[edit | edit source]

Dihydroalprenolol was first synthesized in the 1970s as a derivative of the beta blocker alprenolol. It was developed as a tool for studying the beta adrenergic receptor, and has since been used in numerous studies to understand the function and regulation of this receptor.

Pharmacology[edit | edit source]

Dihydroalprenolol is a non-selective beta blocker, meaning it blocks both the beta-1 and beta-2 adrenergic receptors. It is a competitive antagonist, meaning it competes with adrenaline and noradrenaline for binding to the beta adrenergic receptor.

Use in Research[edit | edit source]

In research, dihydroalprenolol is often radiolabeled with tritium (3H-DHA) and used as a radioligand to study the beta adrenergic receptor. This allows researchers to measure the number of beta adrenergic receptors in a tissue, and to study how these receptors are regulated in response to different conditions.

See Also[edit | edit source]

Dihydroalprenolol Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.